J&J's Erleada shows early wins in early prostate cancer but raises big questions for clinicians on June 01, 2026 Cessation of life early-stage Erleada apalutamide heart risk-benefit debate guidelines high-risk Localized locally advanced risk Malignant neoplasm of prostate Progression-Free Survival Stress Fractures +
FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma on November 07, 2025 Approved AQUILA study daratumumab Darzalex Faspro Early Intervention (Education) high-risk Progression-Free Survival Smoldering myeloma United States Food and Drug Administration +
FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People on June 04, 2025 Approved COVID19 (disease) Elderly (population group) high-risk Moderna next-generation Covid vaccine Omicron Omicron JN.1 Restrictions Spikevax United States Food and Drug Administration Vaccines Variant +
AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients on May 09, 2025 Clinical Trials expansion high-risk Imfinzi Malignant neoplasm of urinary bladder +